grant

The role of Chlamydia trachomatis specific HLA-E restricted CD8 T cell responses in clearance of infection

Organization UNIVERSITY OF ALABAMA AT BIRMINGHAMLocation BIRMINGHAM, UNITED STATESPosted 18 Aug 2023Deadline 31 Jul 2026
NIHUS FederalResearch GrantFY2024(TNF)-αAIDS VirusAbdominal TyphusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAfrican American groupAfrican American individualAfrican American peopleAfrican American populationAfrican AmericansAfrican FemalesAfrican WomenAllelesAllelomorphsAnnual ReportsAntibiotic TherapyAntibiotic TreatmentAntigensAutologousBacterial InfectionsBiologicalBlood monocyteC trachomatisC. trachomatisCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCachectinCannot achieve a pregnancyCell BodyCell Mediated ImmunologyCell-Mediated ImmunityCellsCellular ImmunityChlamydiaChlamydia trachomatisClass I AntigensClass I Major Histocompatibility AntigensClinicalCommunicable DiseasesComplex Class 1CytolysisDataDendritic CellsDifficulty conceivingDiseaseDisorderDisproportionate number of femalesDisproportionate number of womenDisproportionately affects femalesDisproportionately affects womenDisproportionately impacts femalesDisproportionately impacts womenDisproportionately in femalesDisproportionately in womenELISAEctopic PregnancyEnrollmentEnteric FeverEnzyme-Linked Immunosorbent AssayFemaleFemale GroupsFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFutureGenus MycobacteriumHIVHL-A AntigensHLA AntigensHLA-AHLA-A geneHLAAHealthcareHistocompatibility Antigens Class IHistoryHumanHuman Immunodeficiency VirusesHuman Leukocyte AntigensIFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune InterferonImmune responseImmunesImmunityImmunological responseIn VitroIndividualInfectionInfectious Disease PathwayInfectious DiseasesInfectious DisorderInfertilityInterferon GammaInterferon Type IILAV-HTLV-IIILeukocyte AntigensLymphadenopathy-Associated VirusLysisM tbM tuberculosisM. tbM. tuberculosisMHC Class I MoleculeMHC Class I ProteinMHC class I antigenMOMPMacrophage-Derived TNFMajor Histocompatibility Complex Class 1Marrow monocyteMediatingMemoryMethodologyMiyagawanellaModalityModern ManMolecularMonocyte-Derived TNFMycobacteriumMycobacterium tuberculosisNatureNucleic Acid Amplification TestsNucleic Acid TestingOutcomePBMCPathogenesisPathway interactionsPeptidesPeripheral Blood Mononuclear CellPersonsPhenotypePhysiologic pulsePlayPreventionProductionPulseReagentRecording of previous eventsReportingResearch ResourcesResourcesRickettsia trachomaeRiskRoleSalmonellaSeminalSexually Transmitted DiseasesSexually Transmitted DisorderSexually Transmitted InfectionT cell responseT-CellsT-LymphocyteT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTestingTimeTransmissionTumor Necrosis FactorTumor Necrosis Factor-alphaTyphoidTyphoid FeverVaccinationVaccine DesignVaccinesVeiled CellsVenereal DiseasesVenereal DisordersVenereal InfectionsViral DiseasesVirus DiseasesVirus-HIVVulnerable PopulationsWomanWomen's GroupWorkaccess disparitiesaccessibility disparitiesbacteria infectionbacteria pathogenbacterial diseasebacterial disease treatmentbacterial infectious disease treatmentbacterial pathogenbedsoniabiologicburden of diseaseburden of illnesscell mediated immune responsecohortdirect applicationdisease burdendisparities in accessenrollenzyme linked immunoassayexperienceextrauterine pregnancyfemale biasfemale morbidityfemale preponderancefertility cessationfertility lossflow cytophotometryglobal healthgranule cellhealth carehistorieshost responseimmune system responseimmunogenimmunogenicimmunoresponseinequality in accessinequity in accessinequity in accessibilityinfection rateinfertileinsightlFN-Gammamajor outer membrane proteinmonocytemorbidity among femalesmorbidity among womenmorbidity in femalesmorbidity in womenmouse modelmtbmurine modelpathogenpathogenic bacteriapathwayperinatal complicationsrate of infectionreproductivereproductive morbidityresponsescreeningscreeningssexually acquired infectionsocial rolethymus derived lymphocytetooltransmission processviral infectionvirus infectionvirus-induced diseasevulnerable groupvulnerable individualvulnerable peoplewomen's morbiditywomen's preponderance
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
Chlamydia trachomatis (CT) infection remains the most prevalent bacterial sexually transmitted infection (STI)

worldwide, with over 120 million new CT infections reported annually. In the US, African Americans and women

are disproportionally affected by CT infection. Although over 1.5 million CT cases were recently reported in the

US, this is likely an underestimation as the above-mentioned vulnerable population experiences inequities in

access to routine healthcare. Women experience a greater burden of CT infection due to many reproductive

complications associated with this infection. To date, prevention and control efforts have not significantly reduced

CT infection rates. In addition, up to 20% of infected persons are reinfected within a year suggesting either a

short lived or suboptimal immunity. In the context of both murine models and human studies, we and others have

previously showed a role of IFN-γ-producing CD4+ T cells in chlamydia clearance and protection against

reinfection. Recent studies in humans have however shown that CD8 T cells could play a role in CT infection as

well. CD8 T cells recognize pathogens in the context of peptides presented by an infected cell via classical MHC-

Ia alleles (in humans, HLA-A, B or C) or non-classical MHC-Ib alleles (in case of humans, HLA-E). Prior work

has shown that HLA-E restricted CD8 T cells (HLA-E/CD8s) exert an important immune-regulatory role in control

of several intracellular bacterial pathogens such as Mycobacterium and Salmonella. The role of HLA-E/CD8s in

CT infection as it pertains to clearance of CT infection is unknown. Two previous human studies examining CD8

T cell responses to CT indirectly demonstrated responses restricted by non-classical HLA-I alleles. However,

the precise nature of this restriction and the role of such cells in disease pathogenesis as it pertains to clearance

of CT infection was not defined. Since HLA-Ia and HLA-Ib (i.e., HLA-E) are ubiquitously co-expressed,

appropriate molecular tools and methodologies are needed to dissect the unique contributions of CD8 T cells

responding to peptides presented via each of these alleles. We have recently generated HLA-E*01:01 and

E*01:03 specific cellular resources that allowed us to identify HLA-E/CD8s and to assess their relevance in the

context of CT infection. Specifically, our preliminary data shows that HLA-E/CD8s producing CD107a/IFN-γ/TNF-

α are preferentially detected in women who clear CT infection. Our overall hypothesis is that HLA-E restricted

CD8 T cells will play an important role in clearance of CT infection in women. In Aim 1, we will determine

if CT-specific HLA-E restricted CD8 T cells play a role in the clearance of CT infection in women. In Aim 2, we

will determine if CT-specific HLA-E restricted CD8 T cells can be primed from CT naïve female donors with no

current or prior CT infection. In summary our completed studies will demonstrate the biological relevance and

functionality of HLA-E restricted CD8 T cell response in clearance of CT infection and thus has direct applications

for immunogen selection for a preventative CT based vaccine.

Grant Number: 5R21AI175809-02
NIH Institute/Center: NIH

Principal Investigator: Anju Bansal

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →